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Background: Chronic wounds are associated with a number of deficiencies in critical wound healing processes,
including growth factor signaling and neovascularization. Human-derived placental tissues are rich in regenerative
cytokines and have been shown in randomized clinical trials to be effective for healing chronic wounds. In this
study, PURION® Processed (MiMedx Group, Marietta, GA) dehydrated human amnion/chorion membrane tissue
allografts (dHACM, EpiFix®, MiMedx) were evaluated for properties to support wound angiogenesis.
Methods: Angiogenic growth factors were identified in dHACM tissues using enzyme-linked immunosorbent assays
(ELISAs), and the effects of dHACM extract on human microvascular endothelial cell (HMVEC) proliferation and
production of angiogenic growth factors was determined in vitro. Chemotactic migration of human umbilical vein
endothelial cells (HUVECs) toward pieces of dHACM tissue was determined using a standard in vitro transwell assay.
Neovascularization of dHACM in vivo was determined utilizing a murine subcutaneous implant model.
Results: Quantifiable levels of the angiogenic cytokines angiogenin, angiopoietin-2 (ANG-2), epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF), heparin binding epidermal growth factor (HB-EGF), hepatocyte
growth factor (HGF), platelet derived growth factor BB (PDGF-BB), placental growth factor (PlGF), and vascular
endothelial growth factor (VEGF) were measured in dHACM. Soluble cues promoted HMVEC proliferation in vitro and
increased endogenous production of over 30 angiogenic factors by HMVECs, including granulocyte macrophage
colony-stimulating factor (GM-CSF), angiogenin, transforming growth factor β3 (TGF-β3), and HB-EGF. 6.0 mm disks of
dHACM tissue were also found to recruit migration of HUVECs in vitro. Moreover, subcutaneous dHACM implants
displayed a steady increase in microvessels over a period of 4 weeks, indicative of a dynamic intra-implant neovascular
process.
Conclusions: Taken together, these results demonstrate that dHACM grafts: 1) contain angiogenic growth factors
retaining biological activity; 2) promote amplification of angiogenic cues by inducing endothelial cell proliferation and
migration and by upregulating production of endogenous angiogenic growth factors by endothelial cells; and 3)
support the formation of blood vessels in vivo. dHACM grafts are a promising wound care therapy with the potential to
promote revascularization and tissue healing within poorly vascularized, non-healing wounds.
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Normal wound healing is a complex biological process
requiring interactions among distinct resident cell types,
as well as inflammatory cells, platelets, and stem cells.
Growth of new blood vessels into the wound through
angiogenesis is a critical aspect of this process, to pro-
mote the adequate delivery of nutrients and regulatory
factors required for tissue remodeling and regeneration.
The term angiogenesis describes the growth of new
blood vessels from preexisting ones. After acute tissue
injury, there is a rapid cascade of events involving the
local release of angiogenic cytokines, including vascular
endothelial growth factor (VEGF), placental growth fac-
tor (PlGF), platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF), transforming growth
factor β (TGF-β), angiogenin, angiopoietin, and other
factors [1,2] by damaged cells and platelets. These factors
lead to rapid destabilization of local preexisting vessels
and activation of local endothelial cells, a process ampli-
fied by further release of growth factors from monocytes,
macrophages, and fibroblasts. The concentration gradient
of angiogenic signals guides activated endothelial cells
to proliferate, migrate, sprout, and invade the extracellular
matrix (ECM) in coordinated fashion, whereby three
dimensional remodeling of vascular tubes creates a
functional new microcirculatory network. As part of
this response, proteolytic enzymes, including matrix
metalloproteinases (MMPs), are released by endothelial
cells to disrupt interactions with neighboring cells, facili-
tating endothelial cell adhesion, migration, and growth
factor signaling through the dynamic modulation of integ-
rin receptor expression [2].
In chronic wounds, however, normal healing processes
including angiogenesis are disrupted, resulting in delayed
or inappropriate healing. Chronic wounds often occur in
the presence of systemic diseases such as diabetes and
atherosclerosis, which are accompanied by microvascular
deficiencies [1]. Moreover, a number of cellular and mo-
lecular defects are associated with poor healing of chronic
wounds, including growth factor signaling, imbalances of
MMPs and tissue inhibitors of metalloproteinases (TIMPs),
and impaired recruitment of progenitor cells, suggesting
that the correction of these abnormalities may promote a
more natural healing process [3,4].
Human amniotic membranes have been successfully
used to treat chronic cutaneous wounds [5-8]. Allografts
derived from human amniotic membrane exhibit low
immunogenicity and have shown the ability to reduce
inflammation, pain, and scarring, and accelerate wound
healing [9-15]. In a recent clinical trial published in
2013, the healing rate of diabetic foot ulcers significantly
increased following treatment with dHACM, compared
to those treated with a standard therapeutic regimen,
with 77% and 92% of dHACM wounds healed at weeks4 and 6, respectively, compared to only 0% and 8% of
controls (p ≤ 0.001) [13]. Treatment with dHACM allo-
grafts has also demonstrated improved healing in patients
with a variety of additional wound types for which trad-
itional therapies were ineffective, including venous leg
ulcers, crush injury, arterial insufficiency, immunological
skin disease/scleroderma, and snake bite [14]. Additionally,
refractory wounds that healed after dHACM treatment
were reported not to recur with long-term follow-up [15].
Beyond serving as a protective wound barrier, human
amniotic membrane provides a biological matrix sup-
porting cell proliferation and tissue ingrowth. Growth
factors that play a role in normal wound healing have
also been identified in both fresh and preserved amniotic
tissues, including epidermal growth factor (EGF), bFGF,
keratinocyte growth factor (KGF), TGF-α and -β, hep-
atocyte growth factor (HGF), and nerve growth factor
(NGF) [16-18]. We thus hypothesized that one mechan-
ism by which amniotic membrane therapy accelerates
wound healing is through induction of angiogenesis.
To ensure that safely harvested amniotic tissue allografts
preserve their bioactivity for clinical application, are stable
for long-term storage, and are available for off the shelf
use, MiMedx Group, Inc. (Marietta, GA) has developed
a gentle cleansing and dehydration process (PURION®
Process), described elsewhere [19-21]. PURION® Proc-
essed and dehydrated human amnion/chorion mem-
brane (dHACM) allografts have recently been shown to
contain a multitude of pro-angiogenic growth factors
beyond those listed above, including PDGF-AA, PDGF-
BB, PlGF, granulocyte colony-stimulating factor (GCSF),
and VEGF, among others [22].
The goal of this study was to determine the ability of
PURION® Processed and dehydrated human amnion/
chorion membrane (dHACM) allografts to support and
promote angiogenesis. A thorough characterization of the
angiogenesis-related growth factors within EpiFix® dHACM
advanced wound care product (MiMedx Group, Inc.) was
performed. To examine the ability of dHACM to modulate
endothelial cell behavior, human endothelial cell prolif-
eration, migration, and their production of endogenous
angiogenic factors in vitro in response to dHACM was
determined. In vivo studies were further conducted to
determine the ability of dHACM to support angiogen-
esis in a murine subcutaneous implantation model.
Materials and methods
Dehydrated human amnion/chorion membrane (dHACM)
dHACM is a dehydrated human allograft comprised of
laminated amnion and chorion membranes derived from
the placenta [19-21]. Human placentas were donated
under informed consent following Cesarean sections, as
regulated by the Food and Drug Administration’s (FDA)
Good Tissue Practice and American Association of Tissue
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tious diseases, including human immunodeficiency virus
(HIV), human T-lymphotropic virus (HTLV), hepatitis B
and C, syphilis, and cytomegalovirus (CMV). Amnion and
chorion were isolated from placenta, processed with the
proprietary PURION® Process that involves gentle cleans-
ing of the layers, and then laminated to form the graft,
which was dehydrated under controlled drying conditions
[21]. A specific version of dHACM (EpiFix®, MiMedx
Group) was used as the test material in this study;
therefore, the results of this study apply only to PURION®
Processed dehydrated human amnion/chorion composite
grafts (dHACM).
ELISA assays
The content of angiogenic growth factors in samples of
processed, dehydrated human amnion/chorion grafts
(dHACM) from eight donors was measured with standard
enzyme-linked immunosorbent assays (ELISAs; RayBio-
tech, Inc., Norcross, GA). Weighed, minced dHACM
samples were placed in lysis buffer containing protease
inhibitors for 24 hours at 4°C. Samples were then homoge-
nized, centrifuged to remove tissue residue, and the
amount of specific angiogenic factors in the lysis buffer
was measured in diluted aliquots with standard ELISAs.
Growth factor content was normalized to the dry mass
of starting tissue.
In vitro proliferation of human microvascular endothelial
cells
To prepare extracts of dHACM for cell culture expe-
riments, sterilized grafts were minced and extracted in
Medium 131 (Gibco, Life Technologies Corp. M-131-500,
Carlsbad, CA), with and without supplement, at a concen-
tration of 20 milligrams of tissue per milliliter of medium.
After 24 hours of extraction at 4°C, the tissue residue
was removed by centrifugation and the extract was sterile
filtered. Previous studies have established that a significant
amount of the growth factors and cytokines in dHACM
elute from the tissue under these conditions [22].
Human microvascular endothelial cells (HMVECs; Gibco,
Life Technologies Corp. C-011-5C) from adult dermis were
plated on 96-well plates for 24 hours in Medium 131 with
Microvascular Growth Supplement (Gibco, Life Technolo-
gies Corp. S-005-25). The Microvascular Growth Supple-
ment was comprised of growth factors, hormones, and
tissue extracts necessary for culture of HMVECs, and
the final concentration of supplements in Medium 131 was
4.9% v/v fetal bovine serum, 1 μg/mL hydrocortisone, 3 ng/
mL human fibroblast growth factor, 10 μg/mL heparin,
1 ng/mL human epidermal growth factor, and 0.08 mM
dibutyryl cyclic AMP. After 24 hours to allow for cell adhe-
sion, the medium was aspirated from the wells and replaced
with one of the following: medium lacking supplement(negative control), medium plus supplement (positive
control), or medium containing extracts of dHACM at
2 mg/mL, 1 mg/mL, or 0.5 mg/mL, both with and without
supplement. After 72 hours, the plate was washed to re-
move unattached cells and a CyQuant assay (Molecular
Probes, Life Technologies Corp. C7026) was performed to
quantify DNA content (n = 5). DNA content was translated
to cell number, using a standard curve of known cells as
determined by counting on a hemocytometer.
In vitro production of angiogenic growth factors by
human microvascular endothelial cells
Human microvascular endothelial cells were cultured as
described above in Medium 131 with Microvascular
Growth Supplement for 24 hours on 96-well plates at a
density of 3,500 cells/well. Following 24-hour culture
to allow for cell adhesion, the cells were treated with
dHACM extract in Medium 131 with supplement at 2, 1,
and 0.5 mg/mL concentrations. After 72-hour treatment,
the supernatant from 5 wells per sample group was recov-
ered, pooled, and simultaneously tested for the presence
of 60 growth factors, cytokines, and soluble growth factor
receptors. Quantibody assays (Angiogenesis Array 1000,
RayBiotech, Norcross, GA) were performed on the super-
natant according to the manufacturer’s instructions and
were quantified using a fluorescent microarray scanner
(GenePix 4000B, Molecular Devices, Sunnyvale, CA). A
CyQuant assay was subsequently performed, as described
above, on the adherent cells to determine cell number.
In vitro transwell migration studies with human umbilical
vein endothelial cells
Using a modified Boyden chamber assay, human umbilical
vein endothelial cells (HUVECs) were assayed for che-
motactic cell migration toward dHACM tissue. Migration
assays were performed in 24-well transwell inserts with
8 μm pore membrane filters (Corning, Corning, NY).
600 μL of supplement-free culture medium was loaded
into the bottom wells, followed by the addition of
differently sized portions of dHACM tissue, including
2.0 and 6.0 mm diameter disks (n = 4 dHACM tissue
donors tested). Supplement-free Medium 200 (basal
medium; Gibco, Life Technologies Corp. M-200-500)
and Medium 200 containing Large Vessel Endothelial
Supplement (complete medium; Gibco, Life Technolo-
gies Corp. A14608-01) acted as negative and positive
controls, respectively (n = 4). The Large Vessel Endothelial
Supplement contains fetal bovine serum, hydrocortisone,
human epidermal growth factor, human basic fibroblast
growth factor, heparin, and ascorbic acid, optimized for
culture of HUVECs (Gibco, Life Technologies Corp. C-
003-5C). 3.3 × 104 HUVECs (passage 5) were seeded into
the transwell inserts in 100 μl basal medium and cultured
for 24 hours to permit migration.
Table 1 Angiogenic growth factor and cytokine content
in dHACM grafts (n = 8 donors)
Average content












Koob et al. Vascular Cell 2014, 6:10 Page 4 of 10
http://www.vascularcell.com/content/6/1/10After 24 hours, both sides of the inserts were rinsed
with PBS, and non-migrating cells were removed with a
cotton-tipped swab. Remaining cells were fixed in 4% for-
maldehyde in PBS for 30 minutes, and stained with 4’,
6-diamidino-2-phenylindole (DAPI) for 5 minutes prior
to imaging in PBS on a fluorescence microscope (EVOS
FL Auto, 10× objective, Life Technologies). Migrated
cells were counted and averaged across four micrographs
per insert.
dHACM implantation and tissue harvest
Murine experiments conducted at Stanford University
School of Medicine were approved by the Administrative
Panel on Laboratory Animal Care (APLAC), protocol
#20627. dHACM products from six donors were utilized
in a simple subcutaneous implant model. Briefly, 4-month-
old C57BL/6 J mice (Jackson Laboratories, Bar Harbor,
ME) were anesthetized and prepped before a horizontal
6 mm incision was created on the dorsum. A subcutane-
ous pocket was bluntly dissected in the fascial plane under-
lying the panniculus carnosus, and a 5 × 5 mm square of
dHACM was surgically placed. At days 3, 7, 14, and 28
post operation, a cohort of mice (n = 3 per time point) was
sacrificed, and the implant and overlying skin were har-
vested for histological analysis. Uninjured skin and sham-
implanted sites (injured skin) were also collected as refer-
ences for normal and post-injury cutaneous vascularity.
Histological analysis of implant neovascularization
Tissue was harvested and embedded in OCT (Sakura
Finetek USA, Inc., Torrance, CA). 10 μm thick frozen
sections were fixed in acetone and immunostained using
an antibody against CD31 (1:200, Abcam, Cambridge,
MA). Nuclei were stained with DAPI. Randomized,
duplicate microvessel counts per high power field (400×)
were conducted on each skin or intra-implant sample
following CD31 staining. To avoid sampling error, micro-
vessels were defined as distinct areas of positive staining
having a length to width ratio greater than or equal to
one, and in close association with nuclei.
Statistical analyses
Statistical comparisons were performed by using two-
tailed, unpaired Student’s t-tests with significance set at
p ≤ 0.05 to compare treatment groups to their respective
controls. Two sample, two-tailed power analyses (α =
0.05) demonstrated that the statistical power of all tests
was greater than 0.89. All values were expressed as the
mean ± standard deviation.
Results
Angiogenic factors in dHACM
ELISAs performed on dHACM samples showed quanti-
fiable levels of the following angiogenic growth factors:angiogenin, angiopoietin-2 (ANG-2), epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF), hep-
arin binding epidermal growth factor (HB-EGF), hepato-
cyte growth factor (HGF), platelet derived growth factor
BB (PDGF-BB), placental growth factor (PlGF), and vas-
cular endothelial growth factor (VEGF). The amount of
each factor was normalized to the starting dry weight of
the tissue (Table 1).
Endothelial cell proliferation
The human dermal microvascular endothelial cells pro-
liferated to a minor extent in supplement-free medium
(negative control), whereas inclusion of Microvascular
Growth Supplement in the positive control wells caused
the cells to nearly double in number (Figure 1). Extracts
of dHACM caused proliferation of HMVECs in culture.
At all concentrations of the extract, cells proliferated to a
significantly greater extent than their respective controls
(p ≤ 0.05) with or without supplement. There was no dose
response observed among the three extract concentra-
tions, indicating the maximum response was achieved
with these concentrations.
Growth factor production by microvascular endothelial
cells
The effect of dHACM on growth factor production by
human microvascular endothelial cells was examined by
treating cells with extracts of dHACM for three days
and measuring the amount of each growth factor in
the culture medium at the end of the culture period.
Since the extract caused endothelial cells to proliferate
as shown in Figure 1, cell number was measured in each
well after the culture medium was collected, and growth
factor values were normalized on a per cell number. The
amount of each growth factor in the extract itself was
also measured and subtracted from that in the medium
to calculate the amount of additional growth factor pro-
duced by the HMVECs themselves.
Figure 1 Effects of extracts of dHACM on microvascular endothelial cell proliferation in vitro. dHACM extracts promoted proliferation of
HMVECs over controls; however, no dose response was observed at these concentrations. The p values shown indicate statistical significance
from their respective controls. Values shown are means ± standard deviation (n = 5).
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endothelial cells in culture caused by extracts of dHACM
is shown in Figure 2. HMVECs greatly increased produc-
tion of a number of angiogenic factors including granulo-
cyte macrophage colony-stimulating factor (GM-CSF),
angiogenin, TGF-β3, HB-EGF, and interleukin-2 (IL-2)
when cultured in the presence of dHACM extract, com-
pared to untreated cells cultured without extract (Figure 2,
green). HMVECs also increased production of molecules
such as IL-6, angiogenin, and PDGF-BB to a lesser degree
in the presence of extract (Figure 2, blue). A few regula-
tory factors including tumor necrosis factor α (TNF-α)
and IL-10 were down regulated in the presence of extract
(Figure 2, red/yellow), while many factors such as bFGF,
HGF, and TGF-β1 remained unchanged (black), relative to
untreated controls.
Effects of dHACM on HUVEC migration in vitro
HUVEC migration in the basal medium and the smallest
2.0 mm samples was not significantly different; however,
samples containing 6.0 mm diameter disks of dHACM
tissue demonstrated significantly greater migration com-
pared with basal medium and 2.0 mm samples (Figure 3).
No experimental group reached the number of cells com-
parable to complete medium (260 ± 68 cells per field);
however, the 6.0 mm diameter samples demonstrated that
dHACM tissue in the culture medium was capable of
directing endothelial cell migration in vitro.
Neovascular response to dHACM following in vivo
implantation
Immunohistochemical staining for the endothelial cell
specific antigen CD31 was performed to characterize the
neovascular response within implanted dHACM graftsthemselves. The quantity of CD31 positive microvessels
within the dHACM grafts were found to steadily in-
crease through day 28 to levels similar to normal and
healing skin, indicative of dynamic intra-implant neovas-
cularization (Figure 4).
Discussion
These studies clearly demonstrate that dehydrated hu-
man amnion/chorion membranes (dHACM) contain a
large number of pro-angiogenic growth factors, includ-
ing angiogenin, angiopoietin-2, EGF, bFGF, HB-EGF,
HGF, PDGF-BB, PlGF, and VEGF. This partial list of
growth factors does not encompass the entire array of
physiologically important and biologically active mole-
cules present in dHACM [22]. These particular growth
factors, however, are likely to be responsible for the
clinical benefits of this dHACM allograft, in relation to
neovascularization and healing within chronic wounds.
These soluble signals in dHACM also stimulated human
microvascular endothelial cells to proliferate in vitro,
and further, to increase production of a number of
endogenous growth factors, cytokines, and receptors
related to angiogenesis. Furthermore, dHACM tissue
promoted chemotactic migration of human endothelial
cells in vitro, suggesting that these soluble factors are
capable of recruiting endothelial cells to promote
wound re-vascularization. Our findings strongly support
dHACM exerting therapeutic actions both directly and
indirectly by activating multiple signaling pathways that
promote angiogenesis within healing wounds.
Our previous work demonstrated that PURION® Proc-
essed dHACM tissue also retains a collection of growth
factors, anti-inflammatory molecules, and tissue inhibi-
tors of metalloproteinases that play other important
Figure 2 (See legend on next page.)
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Figure 2 Change in growth factor production by human microvascular endothelial cells when cultured in the presence of varying
concentrations of dHACM extract. Endothelial cells increased production of a number of angiogenic factors when cultured in the presence of
dHACM extract, compared to untreated cells cultured without extract (green/blue). A few regulatory factors were also down regulated in the
presence of extract (red/yellow), while many factors remained unchanged (black), relative to untreated controls.
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extracts, promoted the proliferation of dermal fibroblasts
and the recruitment of progenitor cells in vitro and
in vivo [22]. Combined with the present results, dHACM
allografts contain a wide array of soluble signals, only a
fraction of which have been identified to date, which may
stimulate healing through a variety of signaling pathways
and physiological mechanisms.
These multifunctional mechanisms offer advantages
for dHACM as a treatment of difficult to heal chronic
wounds. In normal wounds, the initial fibrin clot acts as
both a matrix for repair and as a reservoir for growth
and cell recruitment factors. Inflammatory cells, including
neutrophils, monocytes, and lymphocytes then invade
the wound and release further growth factors and cyto-
kines that initiate wound repair mechanisms, including
keratinocyte and fibroblast migration/proliferation, micro-
vascular endothelial cell recruitment, proliferation, and
angiogenesis, and nerve sprouting within the granulationFigure 3 Average number of migrated human umbilical vein endothe
human amnion/chorion tissue allografts (dHACM). Representative micr
in response to larger samples, relative to their smaller counterparts. HUVEC
samples (p≤ 0.05). * indicates significantly greater migration than basal metissue [23]. In chronic wounds, however, including dia-
betic and venous ulcers characterized by deficiencies in
vascularization and cytokine signaling, the exogenous deliv-
ery of key cytokines and growth factors may be necessary
to restore a molecular balance and achieve healing [24].
Single growth factors may be insufficient to overcome
to multiple deficiencies in most chronic wounds, as
demonstrated by the modest efficacy and limited utility
of recombinant human PDGF (becaplermin) as a single
agent as shown in a meta-analysis of well-designed clin-
ical trials [25]. By contrast, dHACM contains additional
angiogenic factors, specifically VEGF and bFGF (FGF2),
both potent angiogenic cytokines that promote endothe-
lial cell proliferation and migration [26]. We also identi-
fied PlGF which not only has direct angiogenic effects,
but acts synergistically with VEGF to stimulate wound
angiogenesis [27]. The growth factors angiopoietin-1 and
2 are critical for regulating the stabilization and remod-
eling of blood vessels [23,26]. Our finding that dHACMlial cells (HUVECs) per field of view in response to dehydrated
ographs and cell counts indicated that greater migration was observed
migration in complete medium was significantly greater than all other
dium and 2.0 mm groups (p≤ 0.05). Scale bar – 200 μm.
Figure 4 Neovascular response following in vivo dHACM implantation. An increasing number of CD31 positive microvessels were seen
within the implanted dHACM over time, ultimately reaching the level of normal and previously injured skin by day 28. (A) CD31 positive
microvessels in dHACM over 28 days were stained green, while cell nuclei were counterstained blue with DAPI. (B) Vessel counts demonstrated
an increase in vascularization approaching that of healthy and healing skin after 28 days. Scale bar – 50 μm.
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increase production of a variety of angiogenic cytokines
and growth factors suggests this material’s ability to
amplify the initial signals provided by the allograft itself,
potentially even beyond the lifespan of the allograft.
Previous studies of amniotic membranes in regulating
angiogenesis have reported conflicting data, with some
describing enhanced vascularization while others have
observed inhibition of angiogenesis. Anti-angiogenic
effects have been widely reported in cases of ocular/
corneal surgery [28], while improved vascularization
and healing have been reported when used to promote
healing of cutaneous wounds [29,30]. This dichotomy
may be explained in part by the presence of both anti-angiogenic (including thrombospondin-1, endostatin,
and anti-angiogenic TIMPs) [31] and pro-angiogenic
factors (including VEGF and PDGF) [32,33] in amniotic
tissues. Combined with the previously described role of
the local environment in regulating angiogenesis, the
specific response to the amniotic membrane graft cyto-
kine milieu may thus be largely dependent on the target
tissue and the location of the implantation.
In this study, subcutaneous implantation of dHACM
tissues in a murine model demonstrated a steady in-
crease in vascularization through day 28. More specific-
ally, dHACM implants went from being completely
avascular following implantation, to having a vascular
density similar to both normal and healed skin within
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with our in vitro findings, and consistent with the time
course of clinical trial data [13], supporting the reten-
tion of biological activity by growth factors present in
PURION® Processed dHACM grafts. The prolonged
pro-angiogenic effects from a single implant may offer
potential practical benefits compared to advanced wound
interventions that require more frequent (daily or bi-
weekly) applications.
The angiogenic properties of amniotic membrane grafts
demonstrated here apply only to PURION® Processed,
dehydrated amnion/chorion laminated grafts produced by
MiMedx. The PURION® Process has been optimized to
preserve the bioactivity of native amniotic growth factors
and cytokines, while other amniotic membrane grafts
processed by different methods may not retain biologically
active angiogenic factors and, therefore, may lack the abil-
ity to stimulate angiogenesis. This is particularly true for
single layer amnion products, which are inherently much
thinner and therefore contain far fewer growth factors, as
well as decellularized amniotic membrane grafts, which
have been processed to remove cells and soluble factors
from the tissue matrix.
The clinical value of dHACM grafts for use as therapy
in non-healing wounds has been demonstrated by clin-
ical research, even as further translational studies are
underway. Treatment with dHACM allografts was re-
ported to improve healing in patients with a variety of
wound types for which traditional therapies were inef-
fective [14]. Additionally, refractory wounds that healed
after dHACM treatment were reported not to recur with
long-term follow-up [15]. Finally, in a small, prospective,
randomized clinical trial, Zelen et al. demonstrated a
significant increase in the healing rate of diabetic foot
ulcers treated with dHACM compared to those treated
with a standard therapeutic regimen, with 77% and 92%
of dHACM wounds healed at weeks 4 and 6, respect-
ively, compared to only 0% and 8% of controls [13]. The
aggregate data of dHACM suggests this material could
be studied for comparative effectiveness with other avail-
able wound healing products.
Conclusions
In summary, dHACM allografts derived from human pla-
centa contain multiple angiogenic growth factors with
retained biological activity, directly stimulate angiogenesis,
and encourage amplification of angiogenic signaling cues
by inducing production of endogenous growth factors
from human endothelial cells in vitro. The angiogenic
effects are prolonged to at least 28 days. These properties
help explain the effectiveness of dHACM reported in clin-
ical studies, and suggest the potential of dHACM grafts
to promote revascularization and healing within poorly
vascularized, non-healing wounds and other tissues.Abbreviations
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